Compare VRTX & CMCSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRTX | CMCSA |
|---|---|---|
| Founded | 1989 | 1963 |
| Country | United States | United States |
| Employees | 6100 | N/A |
| Industry | EDP Services | Cable & Other Pay Television Services |
| Sector | Technology | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.7B | 97.9B |
| IPO Year | 1991 | 1972 |
| Metric | VRTX | CMCSA |
|---|---|---|
| Price | $457.11 | $29.30 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 25 | 23 |
| Target Price | ★ $494.64 | $37.79 |
| AVG Volume (30 Days) | 1.6M | ★ 42.7M |
| Earning Date | 02-09-2026 | 01-29-2026 |
| Dividend Yield | N/A | ★ 4.46% |
| EPS Growth | N/A | ★ 62.52 |
| EPS | ★ 14.22 | 6.02 |
| Revenue | $11,723,300,000.00 | ★ $123,311,000,000.00 |
| Revenue This Year | $11.01 | $3.00 |
| Revenue Next Year | $8.74 | $2.24 |
| P/E Ratio | $32.08 | ★ $4.91 |
| Revenue Growth | ★ 10.33 | 0.20 |
| 52 Week Low | $362.50 | $25.75 |
| 52 Week High | $519.68 | $38.46 |
| Indicator | VRTX | CMCSA |
|---|---|---|
| Relative Strength Index (RSI) | 61.34 | 58.42 |
| Support Level | $445.41 | $26.45 |
| Resistance Level | $459.05 | $30.59 |
| Average True Range (ATR) | 10.50 | 0.83 |
| MACD | 0.26 | 0.35 |
| Stochastic Oscillator | 83.14 | 67.75 |
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Comcast is made up of three parts. The core cable business owns networks capable of providing television, internet access, and phone services to 65 million US homes and businesses, or nearly half of the country. The firm provides services to about half of the locations in this territory. Comcast acquired NBCUniversal from General Electric in 2011. NBCU owns several cable networks, including CNBC, MSNBC, and USA, the NBC network, the Peacock streaming platform, several local NBC affiliates, Universal Studios, and several theme parks. The firm plans to spin off most of its cable networks. Finally, Sky, acquired in 2018, is a large television provider in the UK and Italy.